Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Elite Pharma Inc
(OP:
ELTP
)
0.1950
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Elite Pharma Inc
< Previous
1
2
Next >
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
August 14, 2024
Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
August 09, 2024
Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
July 01, 2024
Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
June 26, 2024
Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Exposures
Product Safety
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
February 14, 2024
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
November 14, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
August 14, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
May 20, 2024
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
February 08, 2024
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
December 26, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
December 12, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
November 10, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
August 09, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
June 29, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
June 22, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
September 25, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
September 07, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
August 28, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
May 03, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
April 20, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
February 14, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
November 15, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
November 02, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
February 07, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
December 22, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2023 Financial Results on November 15, 2022
November 08, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information
August 15, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2023 Financial Results on August 16, 2022
August 11, 2022
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information
June 29, 2022
Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT
From
Elite Pharmaceuticals, Inc.
Via
AccessWire
Elite Pharmaceuticals Receives FDA Approval for Generic Sabril(R)
June 29, 2022
NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced...
From
Elite Pharmaceuticals, Inc.
Via
AccessWire
Exposures
Product Safety
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.